title: Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire survey.
abstract: We conducted a questionnaire survey to assess the state of patients with CML after discontinuation of TKI therapy. Nine of 27 patients developed musculoskeletal pain after TKI discontinuation. One had discontinued nilotinib and eight had discontinued imatinib therapy. Median time to symptom development after discontinuation was 2 weeks. Four experienced grade 3 symptoms as per the CTCAE ver. 4.0. One had pain persisting over a period of 21 months. There was a significant difference between patients with and without symptoms as regards female gender and the probability of persistent MMR. Awareness of this withdrawal syndrome after TKI discontinuation is imperative.
authors: Department of Hematology, Tokyo Medical University.
authors: Seiichiro
authors: S
authors: Katagiri
authors: Tetsuzo
authors: T
authors: Tauchi
authors: Yuu
authors: Y
authors: Saito
authors: Tamiko
authors: T
authors: Suguro
authors: Michiyo
authors: M
authors: Asano
authors: Seiichiro
authors: S
authors: Yoshizawa
authors: Juri
authors: J
authors: Sakuta
authors: Daigo
authors: D
authors: Akahane
authors: Yuko
authors: Y
authors: Tanaka
authors: Nahoko
authors: N
authors: Furuya
authors: Keiko
authors: K
authors: Ando
authors: Hiroaki
authors: H
authors: Fujimoto
authors: Seiichi
authors: S
authors: Okabe
authors: Moritaka
authors: M
authors: Gotoh
authors: Yoshikazu
authors: Y
authors: Ito
authors: Kazuma
authors: K
authors: Ohyashiki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D059352:Musculoskeletal Pain / Q000209:etiology*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases